BIIB: Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for BIIB
Across the 3 sessions after earlier BIIB headlines, the stock closed higher 2 times and lower 1 times, with a median move of 0.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BIIB | SPY |
|---|---|---|---|
| Oct 27, 2025 | Health Canada Grants Authorization for "LEQEMBI®" (lecanemab) for the Treatment of Early Alzheimer's Disease | +0.4% | +1.2% |
| Oct 24, 2025 | Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio | -0.1% | +0.8% |
| Oct 22, 2025 | Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 | +1.0% | -0.5% |
Quantisnow market dataNASDAQ
BIIB
Biogen Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for BIIB
Full BIIB profile on Quantisnow Follow BIIB and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time